Femtech Is Not a Niche. It Is Half the Market.
WiLD Norway was proud to take part in Femtech – Half the Market, Double Potential, hosted by VIS together with ConnectVest and partners in Bergen on 16 April. The event brought together founders, investors, researchers, ecosystem leaders and health innovators for an important conversation about one of the most overlooked opportunities in health innovation: women’s health.
From talent to power: New Nordic white paper highlights why women are still not reaching the highest leadership roles
WiLD Norway, together with WiLD in Denmark and VILDA Sweden, has published a new Nordic white paper: From Talent to Power: Why women in Nordic life science are not reaching the highest leadership roles, and what needs to change.
What’s holding femtech back? Our Founder Chelsea Ranger shares her perspective.
Chelsea Ranger, founder of WiLD Norway, is featured in a recent Shifter article and podcast discussing the structural barriers holding back the femtech sector.
90 Million NOK for Women’s Health Research
Norway’s Research Council (Forskningsrådet) just announced 90 million NOK for women’s health research.
And it reflects exactly those priorities WiLD Norway has been advocating for.
An evening with Jens Juul Holst: GLP-1, women’s health, and the evidence we still need
On February 11, WiLD Norway and The Life Science Cluster hosted an evening with Professor Jens Juul Holst, the scientist behind the discovery of GLP-1. Moving beyond headlines about diabetes and weight loss, the discussion explored how GLP-1 biology connects to systemic inflammation, cardiometabolic disease, kidney health, and potential neuroprotection, all highly relevant to women across the life span. Professor Holst framed obesity as a complex, multi-organ condition driven by metabolic mechanisms such as ectopic fat distribution, particularly significant during menopause and midlife transitions. The conversation also addressed real-world questions about long-term use, side effects, equity in access, and the urgent need for sex-specific and life-stage-specific evidence. The evening reinforced WiLD Norway’s commitment to ensuring that research, innovation, and leadership decisions reflect the biological realities of women’s health.
Op-ed: A political decision with major consequences for the innovation economy – taken almost without public debate
An opinion editorial by Chelsea Ranger in Shifter about how Norway is quietly scaling back its life sciences investment, with major consequences for the innovation economy — particularly disadvantaging female founders and women’s health by favoring those who already have capital and networks.
The Nordic Charter for Women’s Health
WiLD Norway is proud to have contributed to the newly launched Nordic Charter for Women’s Health 2040—a groundbreaking framework created to re-frame women’s health as a cornerstone of Nordic resilience, innovation, and equality.
A Shared Vision for Women’s Health Across the Nordics
On December 8, leaders from across the region will gather at the Embassy of Finland in Copenhagen to launch a milestone initiative: the Nordic Charter for Women’s Health 2040.
Women’s Health: Moving from Reports to Action
In a recent opinion piece, NHO Geneo calls for stronger operational leadership in women’s health—emphasizing that we’ve had enough reports. What’s needed now is commitment, resources, and execution.
WiLD Norway Appoints Alfred Bjørlo to Its Board
Women in Life Science Norway (WiLD Norway) has appointed Alfred Bjørlo, former Member of Parliament and health policy spokesperson for the Liberal Party (Venstre), to its Board of Directors.
